Vext Science Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Vext Science hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-47.3%

Rückkaufsrendite

Gesamte Aktionärsrendite	-47.3%
Zukünftige Dividendenrendite	n/a
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

It's Down 26% But Vext Science, Inc. (CSE:VEXT) Could Be Riskier Than It Looks

Oct 24

Take Care Before Jumping Onto Vext Science, Inc. (CSE:VEXT) Even Though It's 30% Cheaper

Jun 18

Shareholders May Be More Conservative With Vext Science, Inc.'s (CSE:VEXT) CEO Compensation For Now

Dec 09

We Think Vext Science (CSE:VEXT) Can Stay On Top Of Its Debt

Sep 29

Vext Science (CSE:VEXT) Seems To Use Debt Quite Sensibly

Apr 29

Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?

Nov 15

Is Vext Science (CSE:VEXT) A Risky Investment?

Jul 15

Weak Statutory Earnings May Not Tell The Whole Story For Vext Science (CSE:VEXT)

Apr 25

Based On Its ROE, Is Vext Science, Inc. (CSE:VEXT) A High Quality Stock?

Jan 15

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von VEXT in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von VEXT gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Vext Science Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von VEXT im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (VEXT)	n/a
Untere 25 % des Marktes (CA)	1.8%
Markt Top 25 % (CA)	6.1%
Branchendurchschnitt (Pharmaceuticals)	2.4%
Analystenprognose (VEXT) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von VEXT im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von VEXT im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von VEXT, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da VEXT keine Ausschüttungen gemeldet hat.

Vext Science Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

New minor risk - Share price stability

Vext Science, Inc. to Report Q3, 2024 Results on Nov 21, 2024

It's Down 26% But Vext Science, Inc. (CSE:VEXT) Could Be Riskier Than It Looks

Vext Science, Inc., Annual General Meeting, Dec 13, 2024

Price target decreased by 14% to CA$0.57

Second quarter 2024 earnings released: US$0.018 loss per share (vs US$0.004 profit in 2Q 2023)

Vext Science, Inc. to Report Q2, 2024 Results on Aug 20, 2024

Price target increased by 12% to CA$0.75

Take Care Before Jumping Onto Vext Science, Inc. (CSE:VEXT) Even Though It's 30% Cheaper

Chief Financial Officer recently bought CA$63k worth of stock

Vext Science, Inc. to Report Q1, 2024 Results on May 29, 2024

New minor risk - Earnings quality

Vext Science, Inc. to Report Q4, 2023 Results on Apr 25, 2024

New major risk - Shareholder dilution

Vext Science, Inc. Announces Transition of Jason Thai Nguyen Out of Executive Role

There Is A Reason Vext Science, Inc.'s (CSE:VEXT) Price Is Undemanding

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vext Science, Inc. to Report Q3, 2023 Results on Nov 28, 2023

Vext Science, Inc., Annual General Meeting, Dec 15, 2023

New major risk - Shareholder dilution

Vext Science, Inc. announced that it has received $11.5 million in funding from LLF Financial S.A.

Is Now The Time To Put Vext Science (CSE:VEXT) On Your Watchlist?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Vext Science, Inc. to Report Q2, 2023 Results on Aug 23, 2023

Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?

Vext Science, Inc. Resigns Stephan Bankosz as Corporate Secretary, Effective August 25, 2023

First quarter 2023 earnings released: EPS: US$0 (vs US$0.016 in 1Q 2022)

Vext Science, Inc. to Report Q1, 2023 Results on May 25, 2023

Price target increased by 7.2% to CA$1.30

Full year 2022 earnings released: EPS: US$0.079 (vs US$0.036 in FY 2021)

Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?

Less than half of directors are independent

Vext Science, Inc. (CNSX:VEXT) entered into agreement to acquire Appalachian Pharm Processing, LLC for $12.5 million.

Vext Science, Inc. Announces Board Changes

Shareholders May Be More Conservative With Vext Science, Inc.'s (CSE:VEXT) CEO Compensation For Now

Price target decreased to CA$1.24

Third quarter 2022 earnings released: EPS: US$0.003 (vs US$0.007 in 3Q 2021)

Less than half of directors are independent

Vext Science, Inc. to Report Q3, 2022 Results on Nov 17, 2022

Price target decreased to CA$1.46

Vext Science, Inc., Annual General Meeting, Dec 15, 2022

We Think Vext Science (CSE:VEXT) Can Stay On Top Of Its Debt

Vext Science Announces Filing of Provisional Patent Application

Sopica Special Opportunities Fund Limited, managed by LLF Financial S.A. acquired a 13.65% stake in Vext Science, Inc. (CNSX:VEXT) from Jason T. Nguyen for $3 million.

Second quarter 2022 earnings released: EPS: US$0.014 (vs US$0.013 in 2Q 2021)

Director recently bought CA$53k worth of stock

Vext Science, Inc. to Report Q2, 2022 Results on Aug 24, 2022

Vext Science, Inc. Announces CFO Transition

First quarter 2022 earnings released

Vext Science, Inc. to Report Q1, 2022 Results on May 30, 2022

Vext Science (CSE:VEXT) Seems To Use Debt Quite Sensibly

Price target decreased to CA$1.84

Less than half of directors are independent

Full year 2021 earnings released: EPS: US$0.036 (vs US$0.023 in FY 2020)

Vext Science, Inc. Announces Executive Changes

Vext Science, Inc. to Report Q4, 2021 Results on Apr 20, 2022

Price target decreased to CA$1.99

Less than half of directors are independent

Vext Science, Inc. Appoints Mark W. Opzoomer as Board of Director

Third quarter 2021 earnings released

Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?

Second quarter 2021 earnings released

Is Vext Science (CSE:VEXT) A Risky Investment?

Vext Science, Inc. (CNSX:VEXT) completed the acquisition of a 72,000 square foot industrial facility in Eloy, Arizona.

First quarter 2021 earnings released

Weak Statutory Earnings May Not Tell The Whole Story For Vext Science (CSE:VEXT)

Full year 2020 earnings released

Vext Science, Inc. Announces CFO Changes

New 90-day high: CA$1.54

Vext Science, Inc. has completed a Composite Units Offering in the amount of CAD 18.032 million.

Vext Science, Inc. announced that it has received CAD 1.5624 million in funding

Based On Its ROE, Is Vext Science, Inc. (CSE:VEXT) A High Quality Stock?

New 90-day high: CA$1.13

New 90-day high: CA$0.95

New 90-day low: CA$0.38